Supernus Pharmaceuticals, Inc. (0LB2.L)

30,34 -0,23 (-0,74%) Alla chiusura: 02:44PM BST

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue
Rockville, MD 20850
United States
301 838 2500
https://www.supernus.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 652

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jack A. Khattar	Founder, President, CEO, Secretary & Director	1,84M	2,34M	1961
Mr. Timothy C. Dec	Senior VP & CFO	704,03k	N/D	1959
Dr. Padmanabh P. Bhatt Ph.D.	Chief Scientific Officer & Senior VP of Intellectual Property	628,41k	153,93k	1957
Mr. Frank Mottola	Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs	526,48k	37,78k	1973
Dr. Jonathan Rubin M.D., MBA	Senior VP of Research & Development and Chief Medical Officer	662,53k	N/D	1961
Mr. Kevin T. Anderson Esq.	Compliance Officer	N/D	N/D	1962
Dr. Todd Horich M.B.A., Ph.D.	Senior Vice President of Marketing & Market Access	N/D	N/D	N/D
Mr. Taylor Raiford	Senior Vice President of Sales	N/D	N/D	N/D
Dr. Bryan A. Roecklein Ph.D.	Senior Vice President of Corporate Development	N/D	N/D	N/D
Mr. Jeff Bozick	Senior Vice President of Supply Chain	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Governance aziendale

L'ISS Governance QualityScore di Supernus Pharmaceuticals, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 7; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.